Dry powder vancomycin compositions and associated methods

Abstract

Dry powder vancomycin compositions and methods for administering and preparing such compositions are provided.

What is claimed is: 
     
         1 . A composition comprising vancomycin or a pharmaceutically acceptable salt thereof, and leucine, wherein vancomycin or the pharmaceutically acceptable salt thereof is present in an amount from about 75% to about 95% by weight of the composition, and wherein the composition is a dry powder. 
     
     
         2 . The composition of  claim 1 , wherein the pharmaceutically acceptable salt comprises vancomycin hydrochloride. 
     
     
         3 . The composition of  claim 1 , further comprising water, wherein water is present in an amount of less than 10% by weight of the composition. 
     
     
         4 . The composition of  claim 1 , wherein an amount of a mode of an aerosol particle size distribution of the composition does not change by more than about 5% after 6 months of storage at 25° C. and 60% relative humidity. 
     
     
         5 . The composition of  claim 1 , wherein an average particle size of the composition does not change by more than 5% after 6 months of storage at 25° C. and 60% relative humidity. 
     
     
         6 . The composition of  claim 1 , wherein the composition provides a median Tmax value between one and three hours. 
     
     
         7 . The composition of  claim 1 , wherein the composition provides a mean maximum blood plasma concentration of vancomycin (Cmax) within the range of about 50% to about 150% of about n×620 ng/mL, wherein n is a value from 0.01 to 10 and n is 1 when the dose of vancomycin is 80 mg. 
     
     
         8 . The composition of  claim 1 , wherein the dry powder composition provides a delivery efficiency of 40% or more. 
     
     
         9 . The composition of  claim 1 , wherein the dry powder composition provides an absolute bioavailability of 40% or more. 
     
     
         10 . The composition of  claim 1 , wherein the vancomycin or the pharmaceutically acceptable salt thereof is present in the dry powder composition in an amount of n×80 mg, and wherein the dry powder composition provides:
 a mean maximum blood plasma concentration of vancomycin (Cmax) within the range of about 50% to about 150% of about n×620 ng/mL; 
 a mean AUC0-24 h value within the range of about 50% to about 150% of about n×6,250 nghr/mL; and 
 a median Tmax value within the range of about 0.5 to about 6 hours, wherein the maximum blood plasma concentration of vancomycin, the AUC0-24 h value, and the Tmax value are the pharmacokinetic parameters following a single pulmonary administration of the dry powder composition; 
 wherein n is a value from 0.01 to 10. 
 
     
     
         11 . The composition of  claim 1 , wherein a stage of an aerosol particle size distribution of the dry powder is not changed by more than 1% after application of 700 mBar of vaccum. 
     
     
         12 . The composition of  claim 11 , wherein the stage comprises a particle size range between about 0.2 μm and about 6.1 μm. 
     
     
         13 . A method comprising administering a dry powder composition comprising vancomycin or a pharmaceutically acceptable salt thereof, and leucine, wherein vancomycin or the pharmaceutically acceptable salt thereof is present in an amount from about 75% to about 95% by weight of the composition to a subject via pulmonary administration. 
     
     
         14 . The method of  claim 13 , wherein the pharmaceutically acceptable salt comprises vancomycin hydrochloride. 
     
     
         15 . The method of  claim 13 , wherein the subject has a condition selected from the group consisting of pneumonia, cystic fibrosis, bronchitis, bronchiectasis, diffuse panbronchiolitis, bronchiolitis, bronchiolitis obliterans, and bronchiolitis obliterans organizing pneumonia (BOOP). 
     
     
         16 . The method of  claim 13 , wherein the composition provides a median Tmax value between one and three hours. 
     
     
         17 . The method of  claim 13 , wherein the composition provides a mean maximum blood plasma concentration of vancomycin (Cmax) within the range of about 50% to about 150% of about n×620 ng/mL, wherein n is a value from 0.01 to 10 and n is 1 when the dose of vancomycin is 80 mg. 
     
     
         18 . The method of  claim 13 , wherein the composition provides a median t½ value greater than 6 hours. 
     
     
         19 . The method of  claim 13 , wherein the dry powder composition provides a delivery efficiency of 40% or more. 
     
     
         20 . The method of  claim 13 , wherein the dry powder composition provides an absolute bioavailability of 40% or more.